secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001600620-24-000001
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia preliminary Q4 net product revenue $42M (+49% YoY); FY23 $159M; guides FY24 $200-220M
--------------------------------------------------------------------------------

- Preliminary net product revenue Q4 2023: ~$42M, up 49% YoY from $28.3M; full-year ~$159M, up 53% from $103.5M.
- Total revenue Q4: ~$45M (+59% YoY); full-year ~$176M (+31% YoY); cash & investments ~$351M at year-end.
- Guides 2024 net product revenue $200-220M; targets cash flow positive in H2 2024.
- Patients on LUPKYNIS therapy: ~2,066 at Dec 31, 2023, up from 1,525 a year earlier; 438 PSFs added in Q4.
- Strategic review process ongoing; no further updates on potential sale or merger at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/0001600620-24-000001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000001/auph-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer